Navigation Links
TYRX Appoints David Elliot, Jr. Chief Operating Officer
Date:12/2/2008

MONMOUTH JUNCTION, N.J., Dec. 2 /PRNewswire/ -- TYRX, Inc., a leader in the development and commercialization of convergent drug-device products, today announced the appointment of David Elliot, Jr. as Chief Operating Officer, responsible for commercial operations.

Mr. Elliot brings over 25 years of experience in the medical device industry. Mr. Elliot joins TYRX from Valam Corp., a privately held company focused on providing laser-based antimicrobial and vascular plaque destruction therapies, where he was President and CEO and remains a Board Director. Prior to Valam, Mr. Elliot was President, COO and Board Director of VistaCare, Inc., a publicly traded hospice care provider. Prior to VistaCare, Mr. Elliot was President, CEO and Board Director of The VASCLIP Company, a privately held medical device company that provides a less invasive surgical alternative to vasectomy. Prior to VASCLIP, Mr. Elliot was the Vice President of Sales and Marketing at Advanced Respiratory, Inc., a privately held company now owned by Hillenbrand Industries, Inc., that sold a proprietary FDA-approved medical device for patients with respiratory issues.

From 1996 to 2001, Mr. Elliot held two senior executive positions (Vice President, Global Marketing of Cardiac Rhythm Management and Director of Corporate Business Development) at St. Jude Medical. In 1987, Mr. Elliot began his career in healthcare executive management at Guidant Corporation, where during the following nine years he held different roles of escalating responsibility and was ultimately the director of Guidant Japan's Cardiac Rhythm Management division. Mr. Elliot earned a Bachelor of Arts in English from Connecticut College and an MBA from the University of Chicago.

"We are thrilled to have David join our management team," said Bill Edelman, President and CEO. "David's experience in the Cardiac Rhythm Management space, as well as his demonstrated track record of achievement in entrepreneurial settings, provides a powerful combination of skills to support the commercialization of our AIGISRx(TM) platform and to advance our forward looking strategies to bring TYRX's unique device/drug products to the market."

"I am excited about joining the TYRX team, which has already launched its first proprietary anti-bacterial device, AIGISRx, has entered a partnership for another, and has a multi-platform pipeline of additional proprietary technologies addressing postsurgical infection and other high cost implant associated morbidities," said Mr. Elliot. "I look forward to adding my business development and marketing experience to the impressive skill set already present at TYRX."

About TYRX, Inc.

TYRX, Inc., an ISO 9001:2000 and ISO 13485:2003 certified medical device manufacturer, commercializes implantable combination drug/device products, including the AIGISRx(TM) Anti-Bacterial Envelope. AIGISRxCRMD contains the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by organisms representing a majority of the infections reported in CRMD related endocarditis, including "superbugs" or MRSA. In addition, AIGISRxis intended to securely hold a pacemaker or implantable cardioverter defibrillator (ICD) in order to create a stable environment when implanted in the body. Following commercial release in June, 2008, AIGISRxhas been implanted in over 1,200 patients nationwide. In February, 2008 TYRX raised $25 million in a venture capital financing led by Clarus Ventures and co-led by Pappas Ventures. TYRX products utilize novel biomaterials, including technology licensed exclusively from Rutgers, The State University of New Jersey. Additionally, TYRX has exclusively licensed from Baylor College of Medicine and The University of Texas M. D. Anderson Cancer Center product patents and associated technologies to address the problem of postsurgical nosocomial infection. TYRX is deploying its capabilities across a broad range of combination implantable medical-pharmaceutical devices. The combination products sector (products incorporating both a drug & a device component) is expected to be the highest growth segment of the medical products industry and TYRX is positioned to be an innovative applications leader in the space.

For more information, please visit www.TYRX.com.

    CONTACT
    Bill Edelman
    President and Chief Executive Officer
    TYRX, Inc.
    732.246.8676
    william@TYRX.com


'/>"/>
SOURCE TYRX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. Novo Nordisk Appoints New Leader of North American Business
3. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
4. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
5. Resonant Medical Appoints New Vice President of Global Sales
6. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
7. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
8. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
9. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
10. Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA
11. Adlyfe Appoints Roxanne Duan as Vice President of Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... LAS VEGAS , June 26, 2016 ... movement to value-based care operating models within the health ... that enable greater financial efficiency , Deloitte offers ... address the key business issues impacting efficient cost optimization: ... alignment , These services facilitate better outcomes and ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
Breaking Medicine Technology: